Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.50 |
| ▸ | CCNC | P24863 | 3/20 | 0.48 |
| ▸ | CDK8 | P49336 | 3/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.45 |
| ▸ | AHR | P35869 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3859271 | 0.99 | RBP4 (0.49) | RBP4CCNCCDK8DYRK1AAHR | |
| SCHEMBL3856255 | 0.87 | RBP4 (0.49) | RBP4CCNCCDK8DYRK1AGSK3B | |
| SCHEMBL1553493 | 0.85 | CHRNA7 (0.56) | RBP4CHRNA7HTR3A | |
| SCHEMBL3861579 | 0.84 | GSK3B (0.52) | RBP4DYRK1AGSK3B | |
| SCHEMBL17347601 | 0.84 | RBP4 (0.48) | RBP4CCNCCDK8DYRK1AAHR | |
| Hydrochloric Acid SCHEMBL3855621 | 0.84 | CHRNA7 (0.55) | RBP4CHRNA7HTR3A | |
| SCHEMBL3859303 | 0.81 | GSK3B (0.37) | RBP4CCNCCDK8DYRK1AGSK3B | |
| SCHEMBL3859306 | 0.81 | RBP4 (0.41) | RBP4DYRK1AGSK3BCHRNA7HTR3A | |
| SCHEMBL4529923 | 0.81 | CCNC (0.42) | RBP4CCNCCDK8DYRK1ACHRNA7 | |
| SCHEMBL3864878 | 0.80 | MAPT (0.42) | RBP4CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589201-B2 | Derivatives of 1,4-diazabicyclo[3.2.1]octanecarboxamide, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-09-15 | — | — | US | claimed |
| US-20070155749-A1 | DERIVATIVES OF 1,4-DIAZABICYCLO[3.2.1]OCTANECARBOXAMIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155749-A1 | DERIVATIVES OF 1,4-DIAZABICYCLO[3.2.1]OCTANECARBOXAMIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CNR1, CNR2, NPY1R | RBP4 2730/4885CCNC 348/4885CDK8 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.